carbamates has been researched along with Allodynia in 44 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effects of retigabine and flupirtine on pain behavior associated with monosodium urate (MSU)-induced gout arthritis." | 7.96 | Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020) |
| "Given that the pharmacological or genetic inactivation of fatty acid amide hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the established involvement of transient receptor potential vanilloid type-1 (TRPV1) channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a model of acute inflammation, and compared its efficacy with that of a single FAAH inhibitor (URB597) or TRPV1 antagonist (capsazepine)." | 7.76 | The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. ( Bettoni, I; Comelli, F; Costa, B; Di Marzo, V; Giagnoni, G; Petrosino, S, 2010) |
| "Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone." | 5.39 | Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013) |
| "N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents." | 5.34 | New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007) |
| "To determine the effects of retigabine and flupirtine on pain behavior associated with monosodium urate (MSU)-induced gout arthritis." | 3.96 | Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020) |
| "JZL195 and the cannabinoid receptor agonist WIN55212 produced dose-dependent reductions in CCI-induced mechanical and cold allodynia, plus side effects including motor incoordination, catalepsy and sedation." | 3.83 | Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model. ( Adamson Barnes, NS; Kazantzis, NP; Mitchell, VA; Vaughan, CW, 2016) |
| " administration of morphine and the selective MAGL inhibitor 2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate (MJN110) were tested alone and in combination at equieffective doses for reversal of CCI-induced mechanical allodynia and thermal hyperalgesia." | 3.83 | The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. ( Abdullah, RA; Akbarali, H; Banks, ML; Cravatt, BF; Dewey, WL; Grim, TW; Lichtman, AH; Mustafa, MA; Niphakis, MJ; Poklis, JL; Wilkerson, JL; Wise, LE, 2016) |
| " Two distinct FAAH inhibitory compounds, URB597 and PF-3845 were tested, and contrasted with standard antinociceptive gabapentin or vehicle treatment, for attenuation of tactile allodynia, cold allodynia, and mechanical hyperalgesia." | 3.81 | Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy. ( Jergova, S; Nasirinezhad, F; Pearson, JP; Sagen, J, 2015) |
| "The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials." | 3.81 | A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015) |
| " In the present study, we conducted a comparative characterization of the effects of the newly identified brain-impermeant FAAH inhibitor, URB937 ([3-(3-carbamoylphenyl)-4-hydroxy-phenyl] N-cyclohexylcarbamate), in various rodent models of acute and persistent pain." | 3.78 | Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. ( Armirotti, A; Bandiera, T; Bertorelli, R; Colombano, G; Moreno-Sanz, G; Piomelli, D; Reggiani, A; Sasso, O; Scarpelli, R, 2012) |
| "Given that the pharmacological or genetic inactivation of fatty acid amide hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the established involvement of transient receptor potential vanilloid type-1 (TRPV1) channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a model of acute inflammation, and compared its efficacy with that of a single FAAH inhibitor (URB597) or TRPV1 antagonist (capsazepine)." | 3.76 | The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. ( Bettoni, I; Comelli, F; Costa, B; Di Marzo, V; Giagnoni, G; Petrosino, S, 2010) |
| "The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists." | 3.73 | Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. ( Cichewicz, DL; Haller, VL; Welch, SP, 2006) |
| "The decreased hyperalgesia was associated with a reduction in CGRP and cytokine gene expression levels in central and peripheral structures and reduced CGRP serum levels." | 1.62 | Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. ( Demartini, C; Francavilla, M; Greco, R; Tassorelli, C; Zanaboni, AM, 2021) |
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "Paclitaxel produced mechanical and cold allodynia without altering nestlet shredding or marble burying behaviors." | 1.48 | Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. ( Hohmann, AG; Iyer, V; Makriyannis, A; Saberi, SA; Slivicki, RA; Vemuri, VK, 2018) |
| "Chronic pain and hyperalgesia, as well as pain resulting from episodes of vaso-occlusion, are characteristic features of sickle cell disease (SCD) and are difficult to treat." | 1.46 | Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis. ( Gupta, K; Simone, DA; Uhelski, ML, 2017) |
| "SA-57 dose-dependently reversed mechanical allodynia in the constriction injury (CCI) of the sciatic nerve model of neuropathic pain and carrageenan inflammatory pain model." | 1.46 | The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. ( Abdullah, RA; Cabrera, R; Cravatt, BF; Ghosh, S; Lichtman, AH; Maldonado, RL; Mustafa, M; Niphakis, MJ; Wilkerson, JL, 2017) |
| "Remarkably, the long-lasting widespread hyperalgesia induced by combining CUS and NGF was effectively reduced by URB597, but not by JZL184." | 1.42 | Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. ( Bindila, L; Hoheisel, U; Lerner, R; Lomazzo, E; Lutz, B; Remmers, F; Schwitter, C, 2015) |
| "Using a rat model of bone cancer pain based on intratibial injection of MRMT-1 tumor cells, we observed a significant increase in C-fiber responses of dorsal horn WDR neurons in the MRMT-1 injected rats, indicating sensitization of spinal WDR neurons in bone cancer rats." | 1.42 | Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain. ( Cai, J; Fang, D; Li, S; Liu, XD; Ren, J; Xing, GG, 2015) |
| "We found that nitroglycerin-induced mechanical allodynia and neuronal activation of the trigeminal nucleus were completely abolished in FAAH-deficient mice." | 1.42 | Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice. ( Markert, A; Nozaki, C; Zimmer, A, 2015) |
| "Orofacial cold hyperalgesia was induced in rats either by the administration of oxaliplatin or by infraorbital nerve chronic constrictive injury." | 1.42 | KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia. ( Abd-Elsayed, AA; Gu, JG; Ikeda, R; Jia, Z; Li, M; Ling, J; Zuo, X, 2015) |
| "Spinal AEA reduces neuropathic pain by acting at both cannabinoid CB1 receptors and transient receptor potential vanilloid-1 (TRPV1) channels." | 1.39 | Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. ( Cristino, L; De Petrocellis, L; Di Marzo, V; Korostynski, M; Makuch, W; Malek, N; Petrosino, S; Przewlocka, B; Slezak, M; Starowicz, K; Zychowska, M, 2013) |
| "Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone." | 1.39 | Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013) |
| "Bone cancer pain has a strong impact on the quality of life of patients, but is difficult to treat." | 1.39 | Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model. ( Cai, J; Fang, D; Han, JS; Liu, M; Wan, Y; Xing, GG; Zheng, Q, 2013) |
| " Cisplatin produces a cumulative toxic effect on peripheral nerves, and 30-40% of cancer patients receiving this agent experience pain." | 1.38 | Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. ( Harding-Rose, C; Khasabov, S; Khasabova, IA; Paz, J; Seybold, VS; Simone, DA, 2012) |
| "Inflammatory hyperalgesia was measured following intraplantar injection of carrageenan." | 1.35 | Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. ( Alexander, SP; Barrett, DA; Bennett, AJ; Chapman, V; Garle, MJ; Jhaveri, MD; Kendall, DA; Patel, A; Richardson, D; Robinson, I; Sagar, DR; Sun, Y, 2008) |
| "Diabetes caused significant hyperalgesia during these tests." | 1.35 | URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats. ( Hasanein, P; Keshavarz, M; Parviz, M; Roohbakhsh, A, 2009) |
| " Oral dosing with URB597 achieved significant, albeit transient, drug levels in plasma, inhibited brain FAAH activity, and elevated spinal cord anandamide content." | 1.34 | The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. ( Calignano, A; Compton, TR; Duranti, A; La Rana, G; Loverme, J; Mor, M; Parrott, J; Piomelli, D; Russo, R; Tarzia, G; Tontini, A, 2007) |
| "N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents." | 1.34 | New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007) |
| "Carbamazepine (100 mg/kg) was weakly effective against all the responses." | 1.31 | Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. ( Field, MJ; Gonzalez, MI; Hughes, J; Singh, L, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (25.00) | 29.6817 |
| 2010's | 29 (65.91) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Greco, R | 1 |
| Demartini, C | 1 |
| Francavilla, M | 1 |
| Zanaboni, AM | 1 |
| Tassorelli, C | 1 |
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 1 |
| Bortolanza, M | 1 |
| Ferreira-Junior, NC | 1 |
| Zhang, F | 1 |
| Liu, S | 1 |
| Jin, L | 1 |
| Tang, L | 1 |
| Zhao, X | 1 |
| Yang, T | 1 |
| Wang, Y | 1 |
| Huo, B | 1 |
| Liu, R | 1 |
| Li, H | 1 |
| Lu, R | 1 |
| Cui, SS | 1 |
| Wang, XX | 1 |
| Chen, L | 1 |
| Liu, F | 1 |
| Gao, J | 1 |
| Wang, W | 1 |
| Uhelski, ML | 1 |
| Gupta, K | 1 |
| Simone, DA | 3 |
| Slivicki, RA | 2 |
| Saberi, SA | 1 |
| Iyer, V | 1 |
| Vemuri, VK | 1 |
| Makriyannis, A | 1 |
| Hohmann, AG | 3 |
| Xu, Z | 1 |
| Mali, SS | 1 |
| Starowicz, K | 2 |
| Makuch, W | 2 |
| Korostynski, M | 1 |
| Malek, N | 2 |
| Slezak, M | 1 |
| Zychowska, M | 1 |
| Petrosino, S | 2 |
| De Petrocellis, L | 2 |
| Cristino, L | 1 |
| Przewlocka, B | 2 |
| Di Marzo, V | 4 |
| Khasabova, IA | 2 |
| Holman, M | 1 |
| Morse, T | 1 |
| Burlakova, N | 1 |
| Coicou, L | 1 |
| Harding-Rose, C | 2 |
| Seybold, VS | 2 |
| Niphakis, MJ | 3 |
| Cognetta, AB | 1 |
| Chang, JW | 1 |
| Buczynski, MW | 1 |
| Parsons, LH | 1 |
| Byrne, F | 1 |
| Burston, JJ | 1 |
| Chapman, V | 2 |
| Cravatt, BF | 6 |
| Hayashi, H | 1 |
| Iwata, M | 1 |
| Tsuchimori, N | 1 |
| Matsumoto, T | 1 |
| Lomazzo, E | 1 |
| Bindila, L | 1 |
| Remmers, F | 1 |
| Lerner, R | 1 |
| Schwitter, C | 1 |
| Hoheisel, U | 1 |
| Lutz, B | 1 |
| Krustev, E | 1 |
| Reid, A | 1 |
| McDougall, JJ | 1 |
| Gilet, M | 1 |
| Eutamene, H | 1 |
| Han, H | 1 |
| Kim, HW | 1 |
| Bueno, L | 1 |
| Nasirinezhad, F | 1 |
| Jergova, S | 1 |
| Pearson, JP | 1 |
| Sagen, J | 1 |
| Cai, J | 2 |
| Fang, D | 2 |
| Liu, XD | 1 |
| Li, S | 1 |
| Ren, J | 1 |
| Xing, GG | 2 |
| Mrugala, M | 1 |
| Kolosowska, N | 1 |
| Binkowski, M | 1 |
| Czaja, M | 1 |
| Morera, E | 2 |
| Ignatowska-Jankowska, B | 1 |
| Wilkerson, JL | 3 |
| Mustafa, M | 2 |
| Abdullah, R | 1 |
| Niphakis, M | 1 |
| Wiley, JL | 1 |
| Lichtman, AH | 5 |
| Nozaki, C | 1 |
| Markert, A | 1 |
| Zimmer, A | 1 |
| Abd-Elsayed, AA | 1 |
| Ikeda, R | 1 |
| Jia, Z | 1 |
| Ling, J | 1 |
| Zuo, X | 1 |
| Li, M | 1 |
| Gu, JG | 1 |
| Adamson Barnes, NS | 1 |
| Mitchell, VA | 2 |
| Kazantzis, NP | 1 |
| Vaughan, CW | 2 |
| Grim, TW | 1 |
| Mustafa, MA | 1 |
| Abdullah, RA | 3 |
| Poklis, JL | 2 |
| Dewey, WL | 1 |
| Akbarali, H | 1 |
| Banks, ML | 1 |
| Wise, LE | 1 |
| Ghosh, S | 1 |
| Cabrera, R | 1 |
| Maldonado, RL | 1 |
| Jhaveri, MD | 1 |
| Richardson, D | 1 |
| Robinson, I | 1 |
| Garle, MJ | 1 |
| Patel, A | 1 |
| Sun, Y | 1 |
| Sagar, DR | 1 |
| Bennett, AJ | 1 |
| Alexander, SP | 1 |
| Kendall, DA | 1 |
| Barrett, DA | 1 |
| Kinsey, SG | 2 |
| Long, JZ | 1 |
| O'Neal, ST | 1 |
| Boger, DL | 1 |
| Hasanein, P | 1 |
| Parviz, M | 1 |
| Keshavarz, M | 1 |
| Roohbakhsh, A | 1 |
| Costa, B | 1 |
| Bettoni, I | 1 |
| Comelli, F | 1 |
| Giagnoni, G | 1 |
| Xu, W | 1 |
| Wu, Y | 1 |
| Bi, Y | 2 |
| Tan, L | 1 |
| Gan, Y | 1 |
| Wang, K | 2 |
| Naidu, PS | 1 |
| Dudley, DT | 1 |
| Chen, H | 1 |
| Su, J | 1 |
| Cao, X | 1 |
| Bian, X | 1 |
| Sasso, O | 2 |
| Bertorelli, R | 2 |
| Bandiera, T | 1 |
| Scarpelli, R | 1 |
| Colombano, G | 1 |
| Armirotti, A | 1 |
| Moreno-Sanz, G | 2 |
| Reggiani, A | 2 |
| Piomelli, D | 4 |
| Khasabov, S | 1 |
| Paz, J | 1 |
| Guindon, J | 1 |
| Lai, Y | 1 |
| Takacs, SM | 1 |
| Bradshaw, HB | 1 |
| Martucci, C | 1 |
| Realini, N | 1 |
| Dionisi, M | 1 |
| Mengatto, L | 1 |
| Duranti, A | 2 |
| Tarozzo, G | 1 |
| Tarzia, G | 2 |
| Mor, M | 2 |
| Taylor, BK | 1 |
| Zheng, Q | 1 |
| Liu, M | 1 |
| Wan, Y | 1 |
| Han, JS | 1 |
| Passmore, GM | 1 |
| Selyanko, AA | 1 |
| Mistry, M | 1 |
| Al-Qatari, M | 1 |
| Marsh, SJ | 1 |
| Matthews, EA | 1 |
| Dickenson, AH | 1 |
| Brown, TA | 1 |
| Burbidge, SA | 1 |
| Main, M | 1 |
| Brown, DA | 1 |
| Dost, R | 1 |
| Rostock, A | 1 |
| Rundfeldt, C | 1 |
| Jayamanne, A | 1 |
| Greenwood, R | 1 |
| Aslan, S | 1 |
| Haller, VL | 1 |
| Cichewicz, DL | 1 |
| Welch, SP | 1 |
| Liberatore, AM | 1 |
| Schulz, J | 1 |
| Favre-Guilmard, C | 1 |
| Pommier, J | 1 |
| Lannoy, J | 1 |
| Pawlowski, E | 1 |
| Barthelemy, MA | 1 |
| Huchet, M | 1 |
| Auguet, M | 1 |
| Chabrier, PE | 1 |
| Bigg, D | 1 |
| Russo, R | 1 |
| Loverme, J | 1 |
| La Rana, G | 1 |
| Compton, TR | 1 |
| Parrott, J | 1 |
| Tontini, A | 1 |
| Calignano, A | 1 |
| Ortar, G | 1 |
| Cascio, MG | 1 |
| Rossi, F | 1 |
| Schiano-Moriello, A | 1 |
| Nalli, M | 1 |
| de Novellis, V | 1 |
| Woodward, DF | 1 |
| Maione, S | 1 |
| Gonzalez, MI | 1 |
| Field, MJ | 1 |
| Hughes, J | 1 |
| Singh, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-20 | Recruiting | ||
| Genetic, Epigenetic, Psychosocial, and Biological Determinants of Post-surgical Pain After Pectus or Spine Surgery[NCT04031716] | 600 participants (Anticipated) | Interventional | 2018-07-06 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
44 other studies available for carbamates and Allodynia
| Article | Year |
|---|---|
Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.
Topics: Animals; Behavior, Animal; Carbamates; Disease Models, Animal; Endocannabinoids; Hyperalgesia; Male; | 2021 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
Topics: Aminopyridines; Analgesics; Animals; Arthritis, Experimental; Arthritis, Gouty; Behavior, Animal; Ca | 2020 |
Astrocytic c-Jun N-terminal kinase-histone deacetylase-2 cascade contributes to glutamate transporter-1 decrease and mechanical allodynia following peripheral nerve injury in rats.
Topics: Animals; Anthracenes; Astrocytes; Carbamates; Cells, Cultured; Etanercept; Excitatory Amino Acid Tra | 2021 |
Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis.
Topics: Anemia, Sickle Cell; Animals; Arachidonic Acids; Benzamides; Carbamates; Disease Models, Animal; End | 2017 |
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; | 2018 |
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor
Topics: Amidohydrolases; Analgesics; Animals; Antineoplastic Agents; Benzamides; Benzoxazines; Brain; Cannab | 2019 |
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Topics: Amides; Amidohydrolases; Analgesia; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acids; Benzam | 2013 |
Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.
Topics: Animals; Arachidonic Acids; Benzamides; Brain Neoplasms; Cannabinoid Receptor Antagonists; Carbamate | 2013 |
Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors.
Topics: Amidohydrolases; Animals; Blood Glucose; Brain; Carbamates; Diabetes Mellitus, Type 2; Diabetic Neur | 2013 |
Activation of peripheral KCNQ channels attenuates inflammatory pain.
Topics: Animals; Anthracenes; Anticonvulsants; Benzamides; Carbamates; Disease Models, Animal; Electric Stim | 2014 |
Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain.
Topics: Amidohydrolases; Analgesics, Non-Narcotic; Animals; Anxiety; Benzamides; Benzodioxoles; Brain; Carba | 2015 |
Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints.
Topics: Acute Disease; Amidohydrolases; Animals; Arthralgia; Benzamides; Carbamates; Carrageenan; Endocannab | 2014 |
Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation.
Topics: Animals; Benzamides; Carbamates; Colon; Disease Models, Animal; Female; Hyperalgesia; Inflammation; | 2014 |
Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Topics: Amidohydrolases; Amines; Analgesics; Animals; Benzamides; Carbamates; Cyclohexanecarboxylic Acids; D | 2015 |
Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain.
Topics: Acetylcholine; Animals; Anthracenes; Bone Neoplasms; Carbamates; Disease Models, Animal; Female; Hyp | 2015 |
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides | 2015 |
Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
Topics: Analgesics; Animals; Benzodioxoles; Biomimetic Materials; Brain; Cannabinoids; Carbamates; Constrict | 2015 |
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Antagonist | 2015 |
KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia.
Topics: Action Potentials; Animals; Carbamates; Chronic Disease; Cold Temperature; Constriction; Disease Mod | 2015 |
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
Topics: Amidohydrolases; Animals; Benzamides; Benzodioxoles; Benzoxazines; Carbamates; Disease Models, Anima | 2016 |
The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
Topics: Analgesics, Opioid; Animals; Arachidonic Acids; Behavior, Animal; Carbamates; Constriction, Patholog | 2016 |
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Topics: Acetamides; Analgesics; Analgesics, Opioid; Animals; Arachidonic Acid; Arachidonic Acids; Carbamates | 2017 |
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Carrageen | 2008 |
Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Topics: Amidohydrolases; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Benzamides; Benzodioxoles; Ca | 2009 |
URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats.
Topics: Amidohydrolases; Animals; Benzamides; Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; C | 2009 |
The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice.
Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Benzamides; Capsa | 2010 |
Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
Topics: Analgesia; Animals; Anthracenes; Anticonvulsants; Carbamates; Feeding Behavior; Freund's Adjuvant; H | 2010 |
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
Topics: Amidohydrolases; Animals; Arthritis, Experimental; Benzamides; Camphanes; Carbamates; Foot; Genotype | 2011 |
Visceral hyperalgesia induced by forebrain-specific suppression of native Kv7/KCNQ/M-current in mice.
Topics: Animals; Anthracenes; Capsaicin; Carbamates; Hyperalgesia; KCNQ2 Potassium Channel; Magnesium Sulfat | 2011 |
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experiment | 2012 |
Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Ca | 2012 |
Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following c
Topics: Amidohydrolases; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Benzodio | 2013 |
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Burns; Carbamates; Carrageenan; Dose-Response Relation | 2013 |
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Carbamates; Endocannabinoids; Enzyme Inhibitors; Ethan | 2013 |
Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model.
Topics: Animals; Anthracenes; Bone Neoplasms; Carbamates; Carcinoma; Down-Regulation; Female; Ganglia, Spina | 2013 |
KCNQ/M currents in sensory neurons: significance for pain therapy.
Topics: Animals; Anthracenes; Anura; Carbamates; Cells, Cultured; CHO Cells; Cricetinae; Disease Models, Ani | 2003 |
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Topics: Acute Disease; Amines; Analgesics, Opioid; Animals; Carbamates; Cyclohexanecarboxylic Acids; Disease | 2004 |
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Chronic Disease; Disease Models, Animal; Enzyme In | 2006 |
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Topics: Acetaminophen; Amides; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoquinones; Camphanes; | 2006 |
Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.
Topics: Animals; Batrachotoxins; Binding, Competitive; Carbamates; Carrageenan; Humans; Hyperalgesia; Imidaz | 2007 |
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Topics: Administration, Oral; Amidohydrolases; Analgesics; Animals; Benzamides; Capillary Permeability; Carb | 2007 |
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Biphenyl Compounds; Brain; Calcium; Carbama | 2007 |
Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain.
Topics: Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Behavior, Animal; Benzofurans; Ca | 2000 |